FindTrial
Sign In

The effect of the anti-hypertensive drug Telmisartan on inflammation in the vascular wall of an aneurysm of the abdominal aorta.

The effect of Telmisartan on inflammatory processes in the vascular wall of abdominal aortic aneurysms. - TELMI

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2015-003674-32-NL
Enrollment
Unknown
Registered
2015-10-26
Start date
2016-02-23
Completion date
Unknown
Last updated
2016-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal aortic aneurysm with an indication for elective open surgical repair.

Interventions

Trade Name: Telmisartan Product Name: Telmisartan Product Code: RVG 105917 Pharmaceutical Form: Tablet

Sponsors

Leiden University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with an abdominal aortic aneurysm who are planned for elective open surgical repair. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria: 1. Renal insufficiency; eGFR 3 times elevated of normal value) 4. Hypersensitivity for angiotensin II type 1 receptor antagonist or ACE inhibitor 5. Current usage of angiotensin II type 1 receptor antagonist or ACE inhibitor 6. Known significant renal stenosis (>70%) of one or both renal arteries 7. Active gout

Design outcomes

Primary

MeasureTime frame
Main Objective: Exploring the possible effects of the selective angiotensin II type 1 receptor antagonist Telmisartan on inflammatory processes and matrix homeostasis in the human aneurysmal vascular wall.;Secondary Objective: Comparing the effects of Telmisartan on inflammatory processes and matrix homeostasis in vascular wall with human AAA tissue from patients who've been using an ACE inhibitor and control AAA tissue. ;Primary end point(s): Analysis of various markers for inflammatory processes, matrix homeostasis and cell proliferation in the human vascular wall after Telmisartan use. ;Timepoint(s) of evaluation of this end point: After sufficient tissue collection.—

Secondary

MeasureTime frame
Timepoint(s) of evaluation of this end point: After sufficient tissue collection.;Secondary end point(s): Comparing markers for inflammatory processes, matrix homeostasis and cell proliferation in the human vascular wall after Telmisartan use with AAA tissue of patients who've been using an ACE inhibitor or controle tissue.—

Countries

Netherlands

Contacts

Public ContactClinical trials vascular research

Leiden University Medical Center

031715263445

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026